Streptomycin sulfateCAS# 3810-74-0 |
- Gimeracil
Catalog No.:BCC2296
CAS No.:103766-25-2
- Isosafrole
Catalog No.:BCC3976
CAS No.:120-58-1
- Mycophenolate Mofetil
Catalog No.:BCC2290
CAS No.:128794-94-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 3810-74-0 | SDF | Download SDF |
| PubChem ID | 19648 | Appearance | Powder |
| Formula | C42H84N14O36S3 | M.Wt | 1457.38 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 100 mg/mL (137.23 mM) DMSO : < 1 mg/mL (insoluble or slightly soluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid | ||
| SMILES | CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O.CC1C(C(C(O1)OC2C(C(C(C(C2O)O)N=C(N)N)O)N=C(N)N)OC3C(C(C(C(O3)CO)O)O)NC)(C=O)O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O | ||
| Standard InChIKey | QTENRWWVYAAPBI-YCRXJPFRSA-N | ||
| Standard InChI | InChI=1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;;;/m00.../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Streptomycin sulfate is an aminoglycoside antibiotic, that inhibits protein synthesis.In Vitro:Strain RB1 shows enhanced susceptibility to streptomycin as the concentration of CV in the growth medium increases. As the CV concentration in the growth medium increases, both cytochrome aa3 levels and streptomycin susceptibility increase. Cytochrome aa3 is necessary for accumulation of streptomycin by B. subtilis[1]. Streptomycin influences tRNA selection. Streptomycin resistance mutations generally map to protein S12 and most of these variants exhibit increased levels of discrimination in the tRNA selection process[2]. References: | |||||
Streptomycin sulfate Dilution Calculator
Streptomycin sulfate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.6862 mL | 3.4308 mL | 6.8616 mL | 13.7233 mL | 17.1541 mL |
| 5 mM | 0.1372 mL | 0.6862 mL | 1.3723 mL | 2.7447 mL | 3.4308 mL |
| 10 mM | 0.0686 mL | 0.3431 mL | 0.6862 mL | 1.3723 mL | 1.7154 mL |
| 50 mM | 0.0137 mL | 0.0686 mL | 0.1372 mL | 0.2745 mL | 0.3431 mL |
| 100 mM | 0.0069 mL | 0.0343 mL | 0.0686 mL | 0.1372 mL | 0.1715 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Streptomycin sulfate
- Perampanel
Catalog No.:BCC1847
CAS No.:380917-97-5
- TACA
Catalog No.:BCC6564
CAS No.:38090-53-8
- Bosutinib (SKI-606)
Catalog No.:BCC1167
CAS No.:380843-75-4
- Pterolactam
Catalog No.:BCN5435
CAS No.:38072-88-7
- [(pF)Phe4]Nociceptin(1-13)NH2
Catalog No.:BCC5778
CAS No.:380620-88-2
- CMPDA
Catalog No.:BCC6151
CAS No.:380607-77-2
- DQP 1105
Catalog No.:BCC6205
CAS No.:380560-89-4
- 187-1, N-WASP inhibitor
Catalog No.:BCC5866
CAS No.:380488-27-7
- alpha-Epoxydihydroartemisinic acid
Catalog No.:BCN5434
CAS No.:380487-65-0
- NBMPR
Catalog No.:BCC7516
CAS No.:38048-32-7
- (+)-columbianetin
Catalog No.:BCN2331
CAS No.:3804-70-4
- Tenovin-1
Catalog No.:BCC2239
CAS No.:380315-80-0
- Brevianamide F
Catalog No.:BCN6452
CAS No.:38136-70-8
- 28-Hydroxy-3-oxoolean-12-en-29-oic acid
Catalog No.:BCN1449
CAS No.:381691-22-1
- Bephenium Hydroxynaphthoate
Catalog No.:BCC3735
CAS No.:3818-50-6
- 7,8-Dihydroxyflavone
Catalog No.:BCC6072
CAS No.:38183-03-8
- Sulindac
Catalog No.:BCC4861
CAS No.:38194-50-2
- Adrenosterone
Catalog No.:BCC4061
CAS No.:382-45-6
- Bacopaside II
Catalog No.:BCC8125
CAS No.:382146-66-9
- Coumarin VI
Catalog No.:BCN7833
CAS No.:38215-36-0
- Pyroxamide
Catalog No.:BCC2424
CAS No.:382180-17-8
- Filixic acid ABA
Catalog No.:BCN6330
CAS No.:38226-84-5
- Anhydroicaritin
Catalog No.:BCN5351
CAS No.:38226-86-7
- Enhydrin chlorohydrin
Catalog No.:BCN4639
CAS No.:38230-99-8
Identification and control of impurities in streptomycin sulfate by high-performance liquid chromatography coupled with mass detection and corona charged-aerosol detection.[Pubmed:21665399]
J Pharm Biomed Anal. 2011 Sep 10;56(2):271-9.
For the control of impurities in Streptomycin sulfate a reversed phase ion-pair high performance liquid chromatography (HPLC) method using charged aerosol detection (CAD) was developed. With this method, 21 impurities could be separated and tentatively identified using a combination of exact mass measurement by TOF-MS and MS/MS experiments with a triple quadrupole MS. For three impurities the suggested structures could be confirmed by in situ formation. The CAD detector response was found to be linear over 2 orders of magnitude allowing a straightforward quantification of all impurities. A limit of quantification of 0.09% for Streptomycin sulfate and of 0.008% for streptidine sulfate (referred to the concentration of the 5mg/ml test solution) could be achieved. The HPLC method was applied to the purity testing of 12 samples of commercially available Streptomycin sulfate from different manufacturers. Impurity levels between 4.6% and 16.0% were found. The current European Pharmacopoeia monograph for Streptomycin sulfate only limits streptomycin B by a TLC test to 3.0%. Therefore, the results of this study underline the importance of introducing a state-of-the-art test for the control of impurities in the monograph. The new HPLC-CAD method is considered suitable for this purpose.
Technology of streptomycin sulfate separation by two-stage foam separation.[Pubmed:22467250]
Biotechnol Prog. 2012 May-Jun;28(3):733-9.
Industrial discharges from manufacturing Streptomycin sulfate (SS) are inhibitory to biological wastewater treatment and need to be stripped of residual SS. For effective SS recovery from the wastewater, a two-stage foam separation technology was investigated using a column with a vertical ellipsoid-shaped channel (VEC) and a conventional one, and sodium dodecyl sulfate (SDS) served as the collector. The mechanism of enhancing foam drainage by VEC was theoretically analyzed. In the first stage, the column with VEC was used and under the optimal conditions of the liquid-loading volume 300 mL, volumetric airflow rate 100 mL/min, the initial pH 7.0 and the molar ratio of SDS to SS 8.0, an improved SS enrichment ratio of 16.7 was obtained. In the second stage, a conventional column was used and with a volumetric airflow rate of 450 mL/min, the foamate had a SS concentration of about 0.5 g/L, so it was used as the feed solution of the first stage. By the two-stage technology, the total SS recovery percentage reached as high as 99.7%. Thus, it was significantly effective for the two-stage foam separation technology to recover SS from the simulative wastewater.
Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood.[Pubmed:24286922]
Int J Pharm. 2014 Jan 30;461(1-2):223-33.
Factors like unreliable and poor oral absorption, including an active Pgp-efflux point towards a compromised oral bioavailability (BA) of Streptomycin sulfate (STRS). Latter instigates its parenteral use (i.m.) only. Furthermore, its chronic use leads to serious side effects like nephrotoxicity and ototoxicity. In the present study, we propose to develop Streptomycin sulfate (STRS) loaded solid lipid nanoparticles (STRS-SLNs) for non-invasive intranasal (IN) delivery. STRS-SLNs were prepared using patented nanocolloidal aqueous dispersion technique (Indian Patent application 3093/DEL/2012). Small particle size (140.1+/-7.0 nm) and significant entrapment efficiency (54.83+/-2.1%) was achieved. Biodistribution studies using (99m)Tc showed a 3.15 and 11.0 times higher concentrations in the brain and blood of mice, respectively, on IN administration of STRS-SLNs in comparison to free (F)-STRS. Lower concentrations (3.3 times) in kidneys implicate lower nephrotoxicity. Similarly a 12 and 4 times lower levels of drug in liver and spleen, respectively upon administration of STRS-SLNs as compared to F-STRS also indicate its lesser accumulation in these reticuloendothelial system organs. Lipophillic enclosure imparted to STRS, coupled with small particle size, and its purported ability to inhibit Pgp-efflux due to the presence of tween 80, is considered to be responsible for a better BA shown by STRS upon incorporation into SLNs. This is predicted to result in an effective treatment of all types of tuberculosis including cerebral tuberculosis as indicated by high relative distribution to brain in comparison to free-STRS.
New insights into early sequential PrPsc accumulation in scrapie infected mouse brain evidenced by the use of streptomycin sulfate.[Pubmed:18224331]
Histochem Cell Biol. 2008 May;129(5):643-50.
To investigate the amplifying potentialities of Streptomycin sulfate in the immunohistochemical (IHC) detection of the abnormal prion protein (PrPsc), we used a sequential brain sampling from C506M3 scrapie strain inoculated C57Bl/6 mice. The weekly removed brains, from 7 to 63 days post intra-cranial inoculation were analysed using PrPsc IHC. The introduction of Streptomycin sulfate, a technique developed for accurate cellular and regional mapping of PrPsc deposition in several animal TSEs, revealed a substantial amplifying effect and a clear specific PrPsc detection as early as 28 days post inoculation. The location of the first detected PrPsc deposits suggests a possible involvement of the cerebrospinal fluid in the early dissemination of the infectious agent. The meaning of these newly accessible PrPsc deposits is discussed in relation to a possible nascent form of PrPsc molecules detected in situ for the first time. Altogether, these findings argue that this method can be highly useful to study the early stages after infection with prion agents.
